Arcturus Therapeutics (NASDAQ:ARCT) updates
on its strategy to rapidly learn about the safety and efficacy profile
of its COVID-19 vaccine using Duke-NUS’ genetic correlation system.
Duke-NUS, the Company’s partner, developed a
process to track genetic changes and their correlations that augment
testing of vaccines.
There are specific gene changes that correlate
directly with efficacy, particularly the level of neutralizing antibody
titers. These gene expression changes can be measured within the first 5
days following vaccination and the data may also guide dose selection.
Arcturus’ COVID-19 vaccine, LUNAR-COV19, is based on its STARR and LUNAR technologies.
https://seekingalpha.com/news/3555824-arcturus-bullish-on-duke-system-in-covidminus-19-vaccine-development
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.